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Abstract Background: The rapid rise in the availability and use of pharmaceutical
agents, and particularly polypharmacy, directly increases the risk for patients
to experience adverse drug reactions (ADRs). There are few studies on the
overall incidence and costs of ADRs.
Objective: The aim of this study was to estimate the incidence and costs of
emergency department (ED) visits related to ADRs for patients greater than
65 years of age using administrative data, and to describe risk factors for
experiencing severe ADRs.
Methods: We employed a retrospective cohort design based on population-
based healthcare administrative clinical databases. Identification of ADR-
related ED visits from the administrative database was based on International
Classification of Diseases, 10th Revision-Canadian Enhancement (ICD-10-CA)
codes for each ED visit. The incidence and costs of ADR-related ED visits and
subsequent hospital admissions were estimated for all adults aged 66 years
and above for the period April 2003–March 2008. Costs were standardized
and reported in 2008 Canadian dollars. Logistic regression was used to detect
risk factors for severe ADRs.
Results: Approximately 0.75% of total annual ED visits among adults aged
66 years and above were found to be ADR-related, and among these patients
21.6%were hospitalized. In 2007, the cost of ADR-related visits was $333 per
ED visit and $7528 per hospitalization for a total annual cost of $13.6million
in Ontario, or an estimated $35.7million in Canada. Severe ADRs were
associated with sex, age, comorbid disease burden, multiple drugs, multiple
pharmacies, newly prescribed drugs, recent ED visit, recent hospitalization
and long-term care (LTC) residence.
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Conclusions: ADRs are an important public health issue that threaten the
safety of drug therapy and results in significant economic burden to the
healthcare system. ED visits related to ADRs may be underestimated in ret-
rospective studies using administrative data compared with prospective
studies. Further research is needed to better understand the risk of experi-
encing severe ADRs among LTC residents.
Background
Several thousands of prescription medications
are currently available. These drugs may cause
adverse drug reactions (ADRs) defined by the
WHO as ‘‘a response to a drug that is noxious
and unintended and occurs at doses normally
used in humans for the prophylaxis, diagnosis or
therapy of disease, or for modification of physi-
ological function’’.[1] ADRs can worsen a patient’s
medical problems, place patients in life-threatening
situations and extend patients’ length of stay in
hospital (thus leading to increased healthcare costs).
A landmark study by Lazarou and colleagues[2]
foundADRs to be among the top six leading causes
of death in the US, with serious ADRs account-
ing for 6.7% of hospitalized admissions.
There are few observational studies of the pop-
ulation incidence and costs of ADRs. While some
pharmacosurveillance studies include multicen-
tre[3] or national hospital data,[4] most studies on
ADRs have been conducted within a single hos-
pital[5] or even a single medical department,[6]
making it difficult to confidently extrapolate re-
sults to a general population.[7] As well, ADRs
occur more commonly in community-dwelling
patients[3] where data is not well documented and
more difficult to obtain. Finally, outpatients pre-
senting to the emergency department (ED) for an
ADR are typically not admitted,[8] and have not
been included in most previous studies. However,
the loss of information from discharged ED
patients may result in the loss of important epi-
demiological information on ADR incidence. We
aimed to obtain population surveillance data for
ADRs and an understanding of its economic
burden. Specifically, we sought the rate of ADRs
that can be observed in EDs and the proportion
of severe ADRs that result in hospitalization or
death. We also quantified the direct hospital care
costs attributable to ADRs from the perspective
of the single-payer government insurance plan.
This population-based retrospective study exam-
ined the incidence and overall costs of ADRs
among patients aged 65 years or older presenting
to hospitals in Ontario, Canada.
Methods
Data Sources
Five linked, cross-sectional and provincially
representative medical administrative databases
were analysed, including the (i) Canadian Institute
of Health Information (CIHI) National Ambu-
latory Care Reporting System (NACRS); (ii) CIHI
Discharge Abstract Database (DAD); (iii) Ontario
Drug Benefit Plan (ODB); (iv) Ontario Health In-
surance Plan (OHIP); and (v) Ontario Registered
Persons Database (RPDB).
NACRS includes data for all Ontario hospital-
based ambulatory care, including day surgery,
outpatient clinics and EDs. The database contains
demographic, clinical and service-specific data.
The DAD includes patient-level data for all acute
hospitalizations in Ontario. Up to 25 diagnosis
codes using International Classification of Diseases,
10th Revision-Canadian Enhancement (ICD-10-
CA) are reported in this database, including one
most responsible diagnosis code and other second-
ary diagnoses. ODB is a publicly funded com-
prehensive drug coverage plan for all Ontario
residents over the age of 65 years. ODB provides
the following information: drugs dispensed, dosage,
days supplied, prescriber information and if the
patient was resident in a long-term care (LTC)
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home at the time a prescription was issued. OHIP
is a government-run health plan for the residents
of Ontario that pays for all medically necessary
physician, hospital and laboratory services. The
OHIP dataset is based on physician billing records
and contains the following information: physician
identifiers, patient identifiers and fee codes for
the medical service provided, diagnosis codes and
date of service.
RPDB contains information on the vital status
of all Ontario residents covered under OHIP.
Demographic information in this study, including
patient age, sex and income level were obtained
from RPDB.
The above databases were linked through com-
mon encrypted health card numbers. The date of
the ED visit was used as the index date. The ad-
ministrative datasets used in this study have been
used extensively for research about prescription
medications.[9-11]
Identification of Adverse Drug Reaction
(ADR)-Related Emergency Department Visits
The study cohort included all Ontario patients
greater than 65 years of age who presented to the
ED with a condition or disorder related to ADRs
between 1 April 2003 and 31 March 2007. Non-
Ontario patients and patients without a valid
Ontario health card number were excluded.
We based our identification of ADR-related
ED visits on codes used in previous research from
the UK.[4] An ED visit record qualified as ADR-
related in one of two ways: (i) there was an ICD-
10-CA diagnosis code for ADR (Appendix table SI,
Supplemental Digital Content [SDC], http://links.
adisonline.com/DSZ/A73) listed in the ‘Main
Problem’ or ‘Other Problems’ fields; or (ii) there
was an ICD-10-CA code of external cause for
ADR (Appendix table SII, online SDC) listed as
‘Other Problems’. Any one indication was suffi-
cient to identify an ADR visit.
Analyses of Incidence of ADRs
The initial ADR-related ED visits identified by
the above method were defined as ADRED. For
patients presenting to the EDwith an ADR-related
problem, after receiving diagnosis and manage-
ment, three possible outcomes were identified:
(i) hospitalization – the patient was admitted
to hospital; (ii) death – the patient died during
the ED visit; and (iii) discharge – the patient
was discharged from the ED. These outcomes
were defined as ADRED-ad, ADRED-died and
ADRED-discharged, respectively.
The incidence of ADRED was calculated for
each fiscal year (1 April–31 March of the follow-
ing year) from 2003 to 2007. Incidence was ex-
pressed as the number of ADRED divided by the
total number of ED visits for patients greater
than 65 years of age for each fiscal year. Within the
cohort of ADRED, the incidence of ADRED-ad,
ADRED-died and ADRED-discharged were calcu-
lated using the number of ADRED in the corre-
sponding fiscal year as the denominator. Trends
over time were examined by comparing the in-
cidence in each fiscal year.
Analyses of Costs of ADRs
All costs in EDs and inpatient medical care
are paid by provincial single-payer insurance
programmes in Canada. Individual inpatients
may pay extra for private accommodation or
amenities (telephone, television) but not medical
care. The economic perspective for this study was
therefore the Ontario single-payer government
insurance programme. The economic burden of
ADR-related hospital visits to the healthcare
system was estimated by calculating direct medi-
cal care costs in two stages. Stage one included
costs among patients with ADRED receiving health-
care in the ED; stage two included hospital-
related costs among patients admitted to hospital
(ADRED-ad).
Costs for each ED visit and related hospital
admissions were estimated by multiplying the
patient’s assigned Resource Intensity Weight
(RIW) by the average provincial cost per weight
(unit price) for the corresponding fiscal year.
RIW is a measure of a patient’s relative resource
consumption compared with an average typical
inpatient cost during a particular hospital sepa-
ration. RIW is calculated annually from DAD,
NACRS and Canadian case-cost data.[12] RIW
for the year 2008 was used for all ED visits and
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hospital admissions to make the data compar-
able. The total cost was the sum of the cost of all
corresponding ED visits and hospital admissions.
Unit prices were updated to the last observed
period of data based on the Consumer Price Index
for healthcare in Ontario[13] and are expressed in
2008 Canadian dollars. A small number of pa-
tients presenting to the ED were admitted to
hospital prior to the study end date of 31 March
2008 but discharged after the study end date.
Because the database was censored at the study
end date, costs could not be estimated for these
patients but these patients were still included in
other analyses.
Risk Factors for Severe ADRs
Patients who presented to the ED with an
ADR-related problem and were then admitted
to or died in the ED represent severe ADRs.
These two categories of patients, i.e. ADRED-ad
and ADRED-died, were combined and coded
as ADRsevere. Patients who presented to the ED
with an ADR and were subsequently discharged,
i.e. ADRED-discharged, were categorized as ADRmild.
Multiple logistic regression analyses were
applied to evaluate risk factors for experiencing
severe ADRs for April 2007–March 2008. The
regression model included measures of patient
demographics, disease burden and care indica-
tors: age, sex, income quintile, Charlson Comor-
bidity Index,[14,15] number of distinct prescription
drugs/prescribers/pharmacies used in a 1-year
period prior to the patient’s visit to the ED, newly
filled prescriptions, recent hospitalization, recent
ED visit, whether the patients had a family phy-
sician and whether the patient resided in an LTC.
Income quintiles (with 1 being the lowest) were
calculated using neighbourhood income per per-
son equivalent, which is the average household
income adjusted by the household size based
on 1996 Canadian census data at the level of
enumeration area.[16] The Charlson Comorbidity
Index for each patient was calculated from a 5-year
look-back for the 17 Charlson Comorbidity Di-
agnoses. The history of drug therapy was examined
for each patient based upon a distinct prescrip-
tion drug count from the 1-year period prior to
the ED visit. The number of distinct prescribers
and pharmacies were also calculated in this manner.
Newly filled prescriptions included changes in
brands for drugs with the same generic name,
changes in doses for the same drug, as well as
commencing new pharmaceutical agents within
30 days prior to the ED visit. Recent hospitali-
zation/ED visit were identified if they occurred
within 30 days prior to the current ED presentation.
Statistical Analyses
All statistical analyses were conducted using
SAS for UNIX, version 9.1 (SAS Institute, Cary,
NC, USA). Two-tailed p< 0.05 was considered sta-
tistically significant. Continuous variables were
summarized usingmean– SD. Categorical variables
were presented as observed number and propor-
tion. Continuous, ordinal and categorical vari-
ables were compared using the Student’s t-test,
the Wilcoxon rank test and the Chi-squared test,
respectively.
A logistic regression model was first developed
to evaluate odds ratios (ORs) and their 95% con-
fidence intervals (CIs) to predict severeADRs based
on all potential risk factors. Starting with the
full model, including all measured independent
variables, the backward selection method was
conducted manually. Then, the final model was
developed by eliminating all potential predictors
that had no statistically significant regression co-
efficients (p > 0.10). Collinearity diagnostics first
examined correlations among all independent vari-
ables, and then multiple linear regression with all
independent variables in the final model was con-
ducted to generate a variance inflation factor (VIF).
VIF greater than 10 was used to assess collinearity
among independent variables.[17] Model diagnostics
were conducted to test the goodness of fit, adequacy
and accuracy of the final model. ORs with 95% CIs
and the corresponding p-value were reported for
all independent variables.
Results
Analyses of Incidence of ADRs
From 2003 through to 2007, the total ED visits
in Ontario for patients aged 65 years and older
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increased from 826 761 in 2003 to 966 232 in 2007;
similarly, the ADR-related ED visits increased
from 6040 in 2003 to 7222 in 2007. (Each year in-
cludes data from April through to March in the
subsequent year although we refer only to the first
year for readability.) Among the ADR-related
ED visits in 2007, 1250 reported the ADR as the
main problem. ADR as an external-cause for a
non-ADRmain problem accounted for the remain-
ing 5972 ED visits. For comparison, the popula-
tion of Ontario reported in the 2006 census was
12.160million people with 13.6% or approxi-
mately 1.65million individuals aged 65 years and
older. The total incidence of ADR-related ED
visits ranged from 0.73% to 0.76%, the incidence
of ADR with diagnosis codes was 0.13–0.15%,
and the incidence of ADR with external cause
codes was 0.67–0.70%. Between 2003 and 2007,
total ED visits for all causes increased by 16.87%,
while the total ADR-related ED visits increased
by 19.57% (largely due to an increase in ex-
ternal cause codes), which indicates a slight in-
crease in the proportion of ADR-related ED
visits (table I).
The most common diagnoses (after ‘unspecified
adverse drug effect’) in the ED for patients with
ADRs (including both main reasons and external
causes), was mental disorders due to multiple
psychoactive drugs, mental disorders due to opi-
oids and mental disorders due to sedatives or
hypnotics, for all the patients with ADRED and
across patients experiencing severe ADRs and
mild ADRs as well. In total, these three diagnoses
accounted for 25% of severe ADRs and 33% of
mild ADRs in 2007.
After being diagnosed and/or managed in the
ED with an ADR-related condition, most pa-
tients were discharged. However at least one in
five patients was admitted to hospital due to the
severe ADRs, and a small portion of patients died
in the ED. The proportion of patients admitted
(21%), discharged (78%) or died (0.07%) among
all patients with ADRED was approximately stable
from 2003 through to 2007 (table II).
The most common principal diagnoses among
inpatient admissions was agranulocytosis (9.44%),
followed by heart failure (3.64%), abnormalities
of heart beat (3.24%), other coagulation defects
(3.17%) and poisoning by agents primarily af-
fecting the cardiovascular system (3.03%), which
were directly or indirectly associated with heart
diseases.
Analyses of Costs of ADRs
The average cost for each individual patient
was stable from 2003 through to 2007. However
due to the increasing volume of patients, the total
cost in constant 2008 dollars for the cohort of
patients with ADRED increased 23% for those
with ED visits only and 17% for those admitted to
hospital (table III).
In 2007, 7222 patients with ADRED cost the
system $2 408 325 for healthcare in the ED.While
5660 patients with mild ADRs cost $235 per
person for an ED visit, the average cost for those
with severe ADRs was $691. In addition, after
being admitted to hospital, patients with severe
ADRs cost an average $7529 per person during
their hospital stay. The total measured costs of
ADR-related ED visits and subsequent hospita-
lizations amounted to $13.6million in 2007.
Risk Factors for Severe ADRs
There were 7222 ED visits for patients greater
than 65 years of age identified with ADRs in













Total no. of ED visits 826 761 (100) 891 027 (100) 910 173 (100) 947 799 (100) 966 232 (100) 16.87
No. with diagnosis codes 1 231 (0.15) 1 289 (0.14) 1 332 (0.15) 1 343 (0.14) 1 250 (0.13) 1.54
No. with external cause codes 5 523 (0.67) 6 058 (0.68) 6 343 (0.70) 6 622 (0.70) 6 724 (0.70) 21.75
Total ADR visits (ADRED) 6 040 (0.73) 6 596 (0.74) 6 930 (0.76) 7 160 (0.76) 7 222 (0.75) 19.57
ADR = adverse drug reaction; ADRED= initial ADR-related ED visits; ED = emergency department.
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2007. Of these visits, 5660 (78.37%) were judged
as mild, while 1562 (21.63%) were identified as
having severe ADRs. Female patients repre-
sented 61% of ADR-related ED visits. The ma-
jority of patients had their own family physicians
(95%), while only 4% were LTC residents at the
time of presenting to the ED. The mean age of
the overall population was 77 years. The mean
Charlson Cormobidity Index was 3.6. More than
half of the patients (60.0%) took over 11 distinct
drugs in 1 year before they presented to the ED.
In the same period, 85% of the patients had two
or more distinct physician prescribers and 50%
filled their prescriptions in different pharmacies.
Overall, 952 (13.2%) had recent hospital admis-
sions and 2560 (35.5%) had recent ED visits. In
the 30 days prior to their ED visits, a mean (– SD)
of 1.7 – 2.0 new drugs were added to patients’
drug therapy (table IV).
Patients with severe ADRs were older, sicker
and more likely to take more than 11 drugs than
those with mild ADRs. A higher proportion of
patients with severe ADRs were male (44%) com-
pared with patients with mild ADRs (38% male);
LTC residents were similarly more common among
severe ADRs than among mild ADRs. However,
there were no differences in income level and
those having a family physician, but there were
Table II. Outcome of patients who had adverse drug reaction-related emergency department visits
2003 [n (%)] 2004 [n (%)] 2005 [n (%)] 2006 [n (%)] 2007 [n (%)]
Total ADR visits 6040 (100) 6596 (100) 6930 (100) 7160 (100) 7222 (100)
Hospitalized 1293 (21.41) 1358 (20.58) 1394 (20.12) 1497 (20.91) 1557 (21.56)
Died in the ED 5 (0.08) <5 (0.0) <5 (0.0) 5 (0.07) 5 (0.07)
Discharged 4742 (78.51) 5235 (79.37) 5534 (79.86) 5658 (79.02) 5660 (78.37)
ADR = adverse drug reaction; ED =emergency department.
Table III. Costs of adverse drug reaction-related emergency department visits and subsequent hospital admissionsa
2003 2004 2005 2006 2007
Costs incurred
in the ED
ADRED Total cost ($) 1 965 075 2117 750 2221 175 2 368925 2 408325
No. of visits 6 040 6 596 6 930 7160 7222
Average cost ($) 325 321 321 331 333
SD ($) 225 216 225 238 232
ADRsevere Total cost ($) 861 875 906 200 930 825 1 034250 1 078575
No. of visits 1 298 1 361 1 396 1502 1562
Average cost ($) 664 666 667 689 691
SD ($) 224 175 227 238 196
ADRmild Total cost ($) 1 103 200 1211 550 1290 350 1 334675 1 329750
No. of visits 4 742 5 235 5 534 5658 5660
Average cost ($) 233 231 233 236 235
SD ($) 104 109 113 117 117
Costs incurred
in hospital
ADRED-ad Total cost ($) 9 544 650 10027 300 9840 150 11 426000 11 164975
No. of admissions 1 289 1 357 1 380 1471 1483
Average cost ($) 7 405 7 389 7 131 7768 7529
SD ($) 9 571 12 187 9 342 11937 11900
a All costs in 2008 Canadian dollars.
ADR = adverse drug reaction; ADRED–ad =ADR diagnosis in ED and then admitted to acute care; ADRED= overall ADR-related ED visits;
ADRmild = admitted to ED with ADR and discharged home; ADRsevere= admitted to ED with ADR and then either admitted or died;
ED = emergency department; SD = standard deviation.
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strong significant differences in other risk factors
(table V).
Consistent with the results of univariate anal-
ysis, multiple logistic regression demonstrated
that females were less likely to have severe ADRs
than males (table VI: adjusted OR 0.81; 95% CI
0.72, 0.92). Age was an independent risk factor
for severe ADRs and the odds of experiencing
severe ADRs increased by 3% per 1-year increase
in age. Severe ADRs occurred more frequently in
patients who had many coexisting conditions.
Compared with those with no Charlson comor-
bidities, a Charlson Index score of 3 or more was
associated with an adjusted OR for severe ADR
of 1.86 (95% CI 1.48, 2.33). The number of dis-
tinct prescription drugs and the number of phar-
macies used in the last year before the ED visit
were both risk factors for severe ADRs. Com-
pared with patients who had 0–5 drugs, patients
taking 6–10 drugs and more than 11 drugs ex-
perienced a risk of severe ADRs that increased by
48% and 93%, respectively. Patients who filled
prescriptions in multiple pharmacies had a higher
risk for severe ADRs (adjusted OR 1.13; 95% CI
1.00, 1.27). Patients were less likely to have severe
ADRs if they had one or two new drugs in their
drug therapy. However, when more new drugs
were added, the protective effect decreased and
was eliminated when there were more than five
new drugs. The odds of having severe ADRs in-
creased by 47% if the patient had a prior hospi-
talization within 30 days prior to the index ED
visit. In contrast, the odds of having severe ADRs
decreased by 27% if the patient had an ED visit
without hospitalization within 30 days prior to
the index ED visit. LTC residents were 2.08 times
more likely to experience severe ADRs than
community residents. No multi-collinearity was
detected in the final variable set. The Hosmer and
Lemeshow goodness-of-fit test’s p-value was larg-
er than 0.05, indicating that the model predicted
the data well, and the c-statistic was 0.667.[18]
Discussion
This is the first population-based research to
study ADR-related ED visits and subsequent
hospital admissions using administrative data in
Canada. This study found that the incidence of
ADR-related ED visits with patients greater than
65 years of age was stable at approximately 0.75%
of all ED visits from 2003 through to 2007, and
the average cost for an individual patient with
ADR-related problems was similarly stable. As a
Table IV. Characteristics of patients having adverse drug reaction-
related emergency department visits in 2007
Variable Prevalence or mean (– SD)
among patients with ADRED
(n =7222)a
Having severe ADRs 1562 (21.6)
Female 4382 (60.7)






Number of drugs used in a




Number of prescribers in a
1-year period prior to index
0–1 1117 (15.5)
2+ 6105 (84.5)
Number of pharmacies used in a
1-year period prior to index
0–1 3644 (50.5)
2+ 3578 (49.5)
Number of new drugs within







Recent hospital admission (Yes) 952 (13.2)
Recent ED visit (Yes) 2560 (35.5)
Family physician (Yes) 6858 (95.0)
Long-term care resident (Yes) 290 (4.0)
a Continuous data presented as mean –SD. Categorical data
presented as observed number (proportion).
ADR(s) = adverse drug reaction(s); ADRED= initial ADR-related ED
visits; ED = emergency department.
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result of the increasing number of ADR-related
acute admissions, total costs increased signif-
icantly in constant dollars. In 2007, the total
measured costs of ADR-related ED visits and
subsequent hospitalizations in Ontario amounted
to $13.6million. If ED presentation for ADR and
severity among adults over 65 years is similar
across Canada, the national annual estimated
cost is $35.7million or $7 per adult over age
65 years. Our study of 7222 elderly patients found
that severe ADRs were associated with sex, age,
comorbidity, multiple drugs, multiple pharmacies,
Table V. Characteristics of patients having adverse drug reaction-related emergency department visits in 2007 according to the severity of
the adverse drug reactionsa
Variable Patients with severe
ADRs (n= 1562) [n (%)]
Patients with mild
ADRs (n =5660) [n (%)]
Significance
(p-value)
Female 878 (56.2) 3504 (61.9) <0.0001
Age (years) 78.4 –7.5 76.6 –7.0 <0.0001
Income quintile NS
1 375 (24.0) 1306 (23.1)
2 349 (22.3) 1241 (21.9)
3 282 (18.1) 1156 (20.4)
4 293 (18.6) 993 (17.5)
5 251 (16.1) 929 (16.4)
Charlson Comorbidity Index <0.0001
0 112 (7.2) 811 (14.3)
1 157 (10.1) 1062 (18.8)
2 234 (15.0) 1029 (18.2)
3+ 1059 (67.8) 2755 (48.7)
Number of drugs used in a 1-year period prior to index <0.0001
0–5 87 (5.6) 742 (13.1)
6–10 351 (22.5) 1711 (30.2)
11+ 1124 (72.0) 3207 (56.7)
Number of prescribers in a 1-year period prior to index 0.0008
0–1 199 (12.7) 918 (16.2)
2+ 1363 (87.3) 4742 (83.8)
Number of pharmacies used in a 1-year period prior to index <0.0001
0–1 716 (45.8) 2928 (51.7)
2+ 846 (54.2) 2732 (48.3)
Number of new drugs within 30 days prior to index <0.0001
0 477 (30.5) 1682 (29.7)
1 364 (23.3) 1643 (29.3)
2 229 (14.7) 1014 (17.9)
3 178(11.4) 573 (10.1)
4 109 (7.0) 334 (5.9)
5+ 205 (13.1) 414 (7.3)
Recent hospital admission (Yes) 287 (18.4) 665 (11.8) <0.0001
Recent ED visit (Yes) 512 (32.8) 2048 (36.3) 0.0127
Family physician (Yes) 1499 (96.0) 5359 (94.7) NS
Long-term care resident (Yes) 131 (8.4) 159 (2.8) <0.0001
a Continuous data presented as mean –SD; statistical significance test was done by two independent sample t-tests.
b Categorical data presented as observed number (proportion); statistical significance test was done by Chi-squared test.
ADRs = adverse drug reactions; ED = emergency department; NS = not significant.
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newly prescribed drugs, recent ED visits, recent
hospitalizations and LTC residents.
The strengths of our study include the longi-
tudinal nature and its comprehensiveness. The
incidence and costs of ADR-related ED visits
were studied over a 5-year period. Our study in-
cluded all ED visits and all acute hospitalizations
in Ontario. Compared with studies conducted
within a single medical unit or hospital, we pro-
vided estimates at the population level without
the issue of lack of representativeness. Our results
are also likely to be representative of care settings
across Canada. Prospective analyses and chart
reviews of ED visits from across the country have
Table VI. Odds ratio of risk factors for experiencing severe adverse drug reactions
Variable Full model (n =7179) Final model (n =7179)
OR (95% CI) p-Value OR (95% CI) p-Value
Female 0.81 (0.72, 0.92) 0.0007 0.81 (0.72, 0.92) 0.0006
Age (years) 1.03 (1.02, 1.04) <0.0001 1.03 (1.02, 1.04) <0.0001
Income quintile
1 Reference
2 1.01 (0.85, 1.20) 0.9284
3 0.91 (0.76, 1.09) 0.2902
4 1.05 (0.88, 1.26) 0.5808
5 1.00 (0.83, 1.21) 0.9972
Charlson Comorbidity Index
0 Reference Reference
1 0.91 (0.70, 1.19) 0.4935 0.91 (0.70, 1.19) 0.4899
2 1.24 (0.96, 1.60) 0.0953 1.24 (0.97, 1.60) 0.0921
3+ 1.84 (1.47, 2.31) <0.0001 1.86 (1.48, 2.33) <0.0001
Number of drugs used in a 1-year period prior to index
0–5 Reference Reference
6–10 1.46 (1.11, 1.90) 0.0061 1.48 (1.13, 1.93) 0.0038
11+ 1.88 (1.44, 2.46) <0.0001 1.93 (1.49, 2.51) <0.0001
Number of prescribers used in a 1-year period prior to index
0–1 Reference
2+ 1.08 (0.90, 1.31) 0.4007
Number of pharmacies used in a 1-year period prior to index
0–1 Reference Reference
2+ 1.11 (0.99, 1.26) 0.08 1.13 (1.00, 1.27) 0.0532
Number of new drugs within 30 days prior to index
0 Reference Reference
1 0.75 (0.64, 0.88) 0.0005 0.75 (0.64, 0.88) 0.0005
2 0.71 (0.59, 0.85) 0.0003 0.71 (0.59, 0.86) 0.0003
3 0.94 (0.76, 1.16) 0.5865 0.95 (0.77, 1.17) 0.6381
4 0.92 (0.71, 1.18) 0.5003 0.92 (0.72, 1.19) 0.5391
5+ 1.16 (0.93, 1.46) 0.1948 1.17 (0.93, 1.47) 0.1822
Recent hospital admission (Yes) 1.47 (1.23, 1.76) <0.0001 1.47 (1.23, 1.76) <0.0001
Recent ED visit (Yes) 0.73 (0.64, 0.84) <0.0001 0.73 (0.64, 0.84) <0.0001
Family physician (Yes) 1.30 (0.95, 1.79) 0.6864
Long-term care resident (Yes) 2.10 (1.63, 2.72) <0.0001 2.08 (1.62, 2.67) <0.0001
ED = emergency department; OR = odds ratio.
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found consistent results in the incidence of ADRs
and presentation to ED.[19,20] An important
weakness with the retrospective analysis of ad-
ministrative databases is that we are not able to
identify which specific drug was the cause for ED
visits or the inpatient admissions.
The estimate of incidence of ADR-related ED
visits in this study is nearly 2-fold higher than that
found in a UK-based retrospective study that
reported that 0.46% of ED visits were related to
ADRs.[21] The fact that the study population in this
study was exclusively seniors while the latter study
included patients of all ages could be one reason for
this difference. Seniors generally have more comor-
bidities and thus take more concurrent drugs.
Although not directly comparable, an incidence
of 0.75% is substantially lower than those from
single-hospital prospective studies, suggesting there
is considerable underestimation of ADRs in ad-
ministrative databases. A study from the US
showed that of 253 ED visits, 8.37% were for
ADRs.[22] An Indian study found 2.66% of the
total 4764 patients presented to the ED because
of ADRs.[23] Another Indian study of patients
greater than age 65 years showed 6.7% of the 578
ED visits were caused by ADRs.[24] A recent
Canadian study reported that 12.0% (122/1017)
of the ED visits were judged as drug-related,
while the most common reason for drug-related
visits were ADRs (39.3%).[25]
Several reasons may account for the under-
estimation. Firstly, with any study of retrospec-
tive design, there is a potential for underestimating
the real incidence because routinely collected data
could be incomplete, inaccurate or missing. Sec-
ondly, our study could not identify all ADR-
related ED visits due to the limitation of the ICD
codes used. The external causes for ADR cover
almost all drug classes that are administered in
current clinical practice, but the diagnosis codes
related to ADR cannot cover all potential ill-
nesses that might be caused by ADRs. Among
cases that were identified by codes of external
cause, only 10% had records of diagnosis related
to ADR. This reflects another limitation of our
study that causality could not be established
without examining detailed information on drug
history and symptoms. Although no studies have
examined the sensitivity and specificity of the
diagnosis of ADR in DAD or NACRS, a valida-
tion study based on chart re-abstraction reported
that most responsible diagnoses were fairly ac-
curate across the DAD.[26] Another validation
study of the ODB reported an overall error rate
of 0.7% with regards to the coding of drug iden-
tifiers, date dispensed, quantity dispensed and
duration of dispensation.[27] RPDB was reported
to have good information on sex and birth dates.[28]
Thirdly, another issue relates to underdiagnosis
by physicians and is related to the current prac-
tice pattern in the ED.[17] While prospective
studies always employ computerized monitoring
programmes and trained professionals to detect
ADRs, ED physicians are responsible for identi-
fying ADRs. Since new drugs are entering the
market at a rapid rate, it is impractical for any
physician to be familiar with all the drugs and
identify countless associated ADRs, especially
when working in a stressed environment. Poor
recognition could account for the low estimate of
the incidence of ADR-related ED visits as noted
in a German study that more than half of the pre-
existing ADRs were not recognized by either the
admitting or the attending physician.[5] Finally,
we note that there is likely to be facility-level
variability in identification and coding of ADRs
in the CIHI databases used in this analysis. Al-
though we do not believe such variability would
be a confounding factor in the present analysis,
future work could investigate such variability.
An important finding is the substantial cost
for patients with severe ADRs. Patients with se-
vere ADRs had ED costs almost three times
greater than patients with mild ADRs, and after
being admitted to hospital, these patients with
severe ADRs cost an additional $11million per
year. This result provides support to the rationale
of this study in exploring risk factors for severe
ADRs. Identifying and potentially reducing the
risks of severe ADRs could result in significant
cost reductions for hospital care. Costs reported
here relate to hospitalizations that resulted from
the onset of an ADR. Some costs for inpatient
hospital stays may have been incurred in provid-
ing treatment for management of conditions not
exclusively related to the ADR. At the same time,
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this study does not include incremental costs
associated with ADRs among patients admitted
to hospital for non-ADR reasons, as has been
done in earlier work.[29]
While some studies have explored factors
associated with the occurrence of all ADRs, this
study also investigated risk factors for (severe)
ADRs presenting in the ED that required hospi-
talization. Any drug could cause an ADR even
when the correct drug is administered properly at
the normal dose. In reality, some mild or even
moderate ADRs, such as rash due to antibiotics
or nausea and vomiting due to antineoplastic agents,
may be reasonably tolerated as long as the drug’s
therapeutic benefit outweighs the known adverse
effects. However, when severe ADRs happen, it
raises the question of whether the harm of a drug
outweighs the benefit. This study makes an im-
portant contribution by investigating risk factors
for severe ADRs, including sex, age, comorbidity,
multiple drugs, multiple pharmacies, newly pre-
scribed drugs, recent ED visit, recent hospitali-
zation and LTC residence.
Consistent with previous work,[30-33] this study
identified ADRs to be more common among fe-
males (60.7% of the overall ADR-related ED
visits) than males. However, females appear to
have a lower risk for experiencing severe ADRs.
This may indicate that females seek medical care
earlier than males. Some studies demonstrated
that when confined to the geriatric age group
in which multiple co-morbidities and multiple
medications are the norm, age itself is not an in-
dependent risk factor for ADR.[34,35] However,
our findings indicated that age itself is an indepen-
dent risk factor for severe ADRs after adjustment
for co-morbidities and multiple medications. This is
supported by higher rates reported by Leendertse
and colleagues[7] where ADR rates among the el-
derly were 3.6% compared with 3.0% among all
hospital admissions.
There is evidence that using multiple medica-
tions can predispose patients to drug-related
problems such as ADRs, drug-drug interactions
and non-compliance.[36-38] In our study the aver-
age number of different drug prescriptions filled
in the year prior to presenting to the ED was 12.9
(not necessarily all simultaneously), and multiple
medications was identified as a risk factor for
severe ADRs. The effect of multiple medications
can also explain why large numbers of drug
changes and the introduction of new drugs within
30 days prior to the ED visit were risk factors
for severe ADRs, while small numbers of drug
changes had a protective effect. Drug changes
could be a result of a recent physician visit, which
could also provide an opportunity for timely de-
tection and intervention on potential medication
problems.
Filling prescriptions at different pharmacies
may be dangerous to patients. Newly added drugs
may interact with older drugs kept in a patient’s
medication regimen and result in drug-related
problems. Pharmacists are trained to identify
and resolve potential drug-related problems but
currently different pharmacies in Ontario do not
share information on a patient’s medication
history. Other clinical interventions that could
potentially reduce the incidence and burden of
ADRs include using a preferred prescriber and
medication reconciliation interventions that in-
clude patient education regarding their medica-
tions.[39-42]
LTC residents were found to be about 2-fold
more likely to experience severe ADRs than
people living at home. Residents of LTC homes
are a particularly vulnerable population as they
often have multiple morbidities and cognitive im-
pairment.[43] Although this study controlled for
risk factors such as age, comorbidity andmultiple
drugs, cognitive impairment could be an un-
measured contributor. Cognitive impairment has
been reported to be a risk factor for adverse drug
events because patients may have difficulty in
understanding instructions for medications and
in managing multiple medications.[44] Among
LTC residents, cognitive impairment may limit
their capacity to report symptoms and adverse
reactions will not be detected early.
Conclusions
ADRs are an important public health issue
that threaten the safety of drug therapy and results
in significant economic burden to the healthcare
system. With far lower rates than those found in
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prospective or trial-based results, our study sug-
gests that ED visits related to ADRs are not well
identified or coded in emergency settings. Since
early identification of an ADR is the predomi-
nant factor in preventability,[5] effective interven-
tions aimed at improving ADR identification are
warranted.
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